XILIO THERAPEUTICS
Live / Registered — Registered (as of 13 Jul 2021)
What this means for you
Registered since 13 Jul 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88981516
- Registration number
- 6421510
- Mark type
- Stylized text
- Filed
- 03 Feb 2020
- Published for opposition
- 02 Jun 2020
- Registered
- 13 Jul 2021
- Attorney of record
- Valerie Brennan
Goods and services
- Class 042 — Scientific and technological services: Pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancer, all of the foregoing excluding research and development services for pharmaceutical products for sleep disorders, central nervous disorders (other than cancers of the central nervous system), and neurological disorders (other than cancers of the neurological system)
Owner
- XILIO DEVELOPMENT, INC., Waltham, MA, US
- XILIO DEVELOPMENT, INC., Waltham, MA, US
- Akrevia Therapeutics, Inc., Cambridge, MA, US
- Akrevia Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 27 Feb 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 27 Feb 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 27 Feb 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 13 Jul 2021 — REGISTERED-PRINCIPAL REGISTER
- 10 Jun 2021 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 09 Jun 2021 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 May 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 May 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 06 Apr 2021 — USE AMENDMENT FILED
- 06 Apr 2021 — SOU EXTENSION 1 GRANTED
- 06 Apr 2021 — SOU EXTENSION 1 FILED
- 03 May 2021 — DIVISIONAL PROCESSING COMPLETE
- 06 Apr 2021 — DIVISIONAL REQUEST RECEIVED
- 26 Apr 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 06 Apr 2021 — TEAS REQUEST TO DIVIDE RECEIVED